Gentian Diagnostics Asa · OSL:GENT
Gentian Diagnostics Asa — Investor Presentation (June 2021)
34 slides from Gentian Diagnostics Asa's investor presentation, June 2021
Slide 1: Innovative and efficient diagnostics
Investor presentation June 2021 Innovative and efficient diagnostics ADDRESSING HIGH-VALUE MARKETS
Slide 2: Important notice
Important notice This presentation has been prepared by and is the sole which are subject to risks, uncertainties and other factors with applicable laws and regulations. The Company require responsibility of Gentian Diagnostics ASA (the “Company” that may cause actual events to differ materially fro
Slide 3: Efficient diagnostics for better treatment decisions
Efficient diagnostics for better treatment decisions «The reason Gentian exists is to deliver diagnostics for better treatment decisions. The high value of the benefits – contributing to protecting life and saving costs – is why our company is faced with a great opportunity» The Gentian team
Slide 4: Gentian management
Gentian management CEO CSO CFO & COO VP R&D VP Clinical Affairs VP Global Sales VP QA & RA VP BD Hilja Erling Njaal Torsten Alexandra Markus Anne-Mette Jack Ibert Sundrehagen Kind Knüttel Havelka Jaquemar Horsrud Akre Andreassen 25+ years’ experience from Erling Sundrehagen, co- 20+ years experience
Slide 5: Gentian Diagnostics develops and supplies innovative and efficient reagents for the clinical diagnostics market
Gentian Diagnostics develops and supplies innovative and efficient reagents for the clinical diagnostics market Sales office, Sweden • Gentian serves the global market for human and veterinary clinical diagnostic tests HQ, Norway • Expertise and focus within immunochemistry, specifically in the dise
Slide 6: Portfolio of high-impact tests provides solid growth opportunity
Portfolio of high-impact tests provides solid growth opportunity 7* tests contributing Annual revenue to saving costs and ambition of NOK protecting life 1bn in 5-7 years Ambition to grow portfolio USD 1.3bn serviceable with 1 new diagnostics market with 8-9% annual product per year* growth Delivere
Slide 7: How Gentian contributes to efficient diagnostics for better treatment decisions
How Gentian contributes to efficient diagnostics for better treatment decisions The industry challenge Gentian’s solution High-value benefits A growing diagnostics market puts increasing Particle-enhanced turbidimetric 3-10x higher throughput significantly pressure on clinical laboratory efficiency
Slide 8: 7 diagnostic tests, including two potential blockbusters
7 diagnostic tests, including two potential blockbusters ESTABLISHED PRODUCTS IN MARKET IN PRODUCT DEVELOPMENT DEVELOPMENT Inflammation Inflammation Kidney disease & infection Inflammation Pancreas & infection Inflammation Cardiac Cystatin C Canine CRP fCAL® fPELA® GCAL® SARS-CoV-2 NT-proBNP 2006 20
Slide 9: Products targeting large and growing disease groups
Products targeting large and growing disease groups DISEASE GROUP PRODUCT APPLICATION ATTRACTIVE CLINICAL BENEFITS Kidney disease Cystatin C Early detection of reduced kidney function Preventing severe kidney failure Inflammation Fast diagnosis of inflammatory bowel disease Reducing time-consuming a
Slide 10: Growing into a serviceable market of USD 1.3bn
Growing into a serviceable market of USD 1.3bn Total Addressable Market, USDbn Total Serviceable Market, USDm - growing at 5-6% p.a. - growing at 8-9% p.a. ~1,300 ~800 USD 1.3 7bn+ ~300 ~200 Established GCAL NT-proBNP Serviceable products market Total Addressable Market Market share ambitions ~25% ~
Slide 11: Solid progress recent years with sales growth and partnerships with leading commercial partners
Solid progress recent years with sales growth and partnerships with leading commercial partners Total revenue, NOKm*, and CAGR Partnerships prove viability of go-to-market model 79 +31% Long-standing commercial partnership for Cystatin C 55 52 Partnership for fCAL initiated 35 through Bühlmann Labor
Slide 12: Long-term ambitions rooted in recent progress
Long-term ambitions rooted in recent progress Four established products with potential to grow 20%+ annually Prove clinical relevance of GCAL and bring NT-proBNP to market 7 products with combined net revenue potential of Launch one new product per year Revenue NOK 1bn ambition of NOK in 5-7 1bn yea
Slide 13: Several de-risking milestones next months
Several de-risking milestones next 18 months ESTABLISHED PRODUCTS GCAL SARS-COV-2 AB NT-PROBNP Targeting additional large Clinical studies confirming Successful validation and Successful verification during commercial partners relevance for sepsis and launch, scheduled for Q4 2021 2021 COVID-19 – 6
Slide 14: Product portfolio and pipeline
Product portfolio and pipeline
Slide 15: Continued strong growth outlook for the established products
Continued strong growth outlook for the established products • 31% revenue CAGR in 2017-2020 Revenue, NOKm • Current serviceable market of ~USD 200m, NOKm +31% 79 growing by 5-10% annually Other revenue 16 Sales revenue 55 • Significant room to expand market access 52 7 through additional commercial
Slide 16: GCAL: Studies and approvals key to market access
GCAL: Studies and approvals key to market access Serviceable Market USDm +15% 694 700 600 500 300 400 300 200 100 0 2020 2021 2022 2023 2024 2025 2026 About GCAL Key value drivers The early inflammation biomarker GCAL is the first Calprotectin test • Clinical studies confirming clinical relevance fo
Slide 17: GCAL addressing life-critical and growing disease
GCAL addressing life- critical and growing disease «Sepsis continues to be a growing problem and the emergence of the COVID-19 pandemic has only increased the attention on caring for infected patients. Early detection is crucial for patients. Approximately 1.7 million individuals in the US develop s
Slide 18: NT-proBNP: Successful 2022 launch no.1 milestone
NT-proBNP: Successful 2022 launch no.1 milestone Serviceable Market USDm +5-8% 1,167 800 2020 2021 2022 2023 2024 2025 2026 About NT-proBNP Key value drivers Measuring NT-proBNP levels in plasma supports diagnosis of congestive • Successful verification during 2021 heart failure. The Gentian assay w
Slide 19: Measuring true NT-proBNP values, Gentian develops an instrument-independent method for consistent results
Measuring true NT-proBNP values, Gentian develops an instrument-independent method for consistent results Existing tests impacted Gentian developing The value of a reference by glycosylation a reference method method • Diagnosis effectiveness dependent on • Accurately measures number of NT-proBNP •
Slide 20: SARS-CoV-2 Ab: Moving towards launch in Q4 2021
SARS-CoV-2 Ab: Moving towards launch in Q4 2021 Serviceable market, Nordics USD 20m ~1% of global market About SARS-CoV-2 Ab Key value drivers The aim with SARS-CoV-2 Ab, measuring COVID-19 immunity, is to • Successful development and launch, scheduled for Q4 2021 offer the first such test for high-
Slide 21: 3 biomarkers in exploration and proof of concept
Products in exploration and ‘proof of concept’ to further drive laboratory productivity and boost revenue and earnings potential 3 biomarkers • On track to launch one new product per year • Main targets in inflammations & infections, with currently in exploration and potential first entry into cance
Slide 22: Combining avian antibodies and PETIA enables fast results and improved lab productivity
Combining avian antibodies and PETIA enables fast results and improved lab productivity Avian antibodies PETIA Avoiding interference enables Removing separation conversion to PETIA steps increases throughput and reduces cost Antibodies: Proteins used by the immune system to identify Immunoassays: Bi
Slide 23: Development process and go-to-market model
Development process and go-to-market model
Slide 24: Structured approach to product development
Structured approach to product development EXPLORATION PROOF OF CONCEPT OPTIMISATION VERIFICATION VALIDATION LAUNCH Clinical and Technical feasibility Prototype developed Prototype formally Final product tested Product made available commercial demonstrated, project and risk assessment evaluated aga
Slide 25: Diversified sales model to ensure broad market access and maximize penetration
Diversified sales model to ensure broad market access and maximize penetration Global diagnostics companies Specialized/local distributors Healthcare providers • Gentian’s main strategy to secure broad roll-out • Accelerating time to revenue and awareness • Direct sales to select end-users and key o
Slide 26: Market, capital priorities and long-term ambitions
Market, capital priorities and long-term ambitions
Slide 27: USD 1.3bn global serviceable market estimated to grow by 8-9% annually next 5-7 years
USD 1.3bn global serviceable market estimated to grow by 8-9% annually next 5-7 years Serviceable Market Total Addressable Total Serviceable Target market share, Gentian’s annual growth rate, Market, USDbn Market, USDm unrisked revenue take next 5-7 years Established products 1.5 180 ~25% 30-50% 5-1
Slide 28: Ambitions for impact, high growth and value creation
Ambitions for impact, high growth and value creation Market opportunity and long-term ambitions Strategic pillars • Grow annual revenue from established products through 5-7 year revenue ambition NOK 1bn additional commercial partners and regulatory approvals • Prove clinical relevance of GCAL for s
Slide 29: Investing to scale with fully funded business plan
Investing to scale with fully funded business plan Q1 2021 financials Capital priorities Sales EBITDA • Opex of NOK 61m and capex of NOK 4m in 2020 NOK 20m NOK -2m • Planned spending increase as total number of +21% vs Q1’20 NOK +3m vs Q1’20 products launched and sales grow – limited increase in cap
Slide 30: Portfolio of high-impact tests provides solid growth opportunity
Portfolio of high-impact tests provides solid growth opportunity 7* tests contributing Revenue ambition to saving costs and of NOK 1bn in protecting life 5-7 years Delivered ~30% Industry leading annual revenue team and knowhow growth 2017-20 * 5 products launched, further 2 in development.
Slide 31: Appendix
Appendix
Slide 32: Gentian board
Gentian board Tomas Espen Tidemann Ingrid Teigland Kari E. Susanne Runar Tomas Settevik Jørgensen Akay Krogstad Stuffers Vatne Kramar Chair of Board member Board member Board member Board member Board member Board member the Board Tomas Settevik has Espen Tidemann Ingrid Teigland Akay is a Kari Krog
Slide 33: Financials
Financials Q1 2021 Q1 2020 FY 2020 Sales revenue 19.6 16.2 63.3 Other operating revenue 4.6 2.9 15.6 Total operating revenue 24.2 19.1 78.9 Costs of goods sold -10.5 -9.9 -32.6 R&D costs -7.7 -5.6 -27.3 Selling, general & administrative costs -9.5 -8.5 -33.6 Capitalization 1.5 0.1 3.4 Total operatin
Slide 34: Top shareholders
Top 20 shareholders Shareholder No of shares % Vatne Equity AS 2,010,224 13.04% Norda ASA 1,250,068 8.11% Holta Life Sciences AS 1,188,702 7.71% Safrino AS 1,050,000 6.81% Salix AS 798,303 5.18% Skandinaviska Enskilda Banken AB 775,437 5.03% Verdipapirfondet Delphi Nordic 749,227 4.86% Verdipapirfon
Gentian Diagnostics — Investor Presentation (June 2021) on 6ix